Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium.
Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT. Russell KL, et al. Cancer J. 2019 May/Jun;25(3):165-177. doi: 10.1097/PPO.0000000000000374. Cancer J. 2019. PMID: 31135523 Free PMC article. Review.
Making cold malignant pleural effusions hot: driving novel immunotherapies.
Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Murthy P, et al. Among authors: russell kl. Oncoimmunology. 2019 Jan 22;8(4):e1554969. doi: 10.1080/2162402X.2018.1554969. eCollection 2019. Oncoimmunology. 2019. PMID: 30906651 Free PMC article. Review.
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
Ekeke CN, Russell KL, Joubert K, Bartlett DL, Luketich JD, Soloff AC, Guo ZS, Lotze MT, Dhupar R. Ekeke CN, et al. Among authors: russell kl. Ann Surg Oncol. 2021 May;28(5):2715-2727. doi: 10.1245/s10434-020-09477-4. Epub 2021 Feb 11. Ann Surg Oncol. 2021. PMID: 33575873 Free PMC article. Review.
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Das R, Blázquez-Gamero D, Bernstein DI, Gantt S, Bautista O, Beck K, Conlon A, Rosenbloom DIS, Wang D, Ritter M, Arnold B, Annunziato P, Russell KL; V160-002 study group. Das R, et al. Among authors: russell kl. Lancet Infect Dis. 2023 Dec;23(12):1383-1394. doi: 10.1016/S1473-3099(23)00343-2. Epub 2023 Aug 31. Lancet Infect Dis. 2023. PMID: 37660711 Clinical Trial.
130 results